[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352843-105":59,"doc-detail-352843-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","adenocarcinoma-of-the-small-intestine-cohort-prospectively-collecting-real-world-data-to-improve-care-and-quality-of-life-for-patients-with-a-rare-cancer","Adenocarcinoma of the small intestine cohort - prospectively collecting real-world data to improve care and quality of life for patients with a rare cancer","","Small intestinal adenocarcinoma (SIA) is a rare cancer with poor prognosis, limited biological understanding, and few randomized trials; treatment is therefore largely extrapolated from other gastrointestinal cancers. The AdenoCarcinoma of the Small Intestine (ACSI) cohort is a subcohort within the Prospective Dutch ColoRectal Cancer (PLCRC) study. It prospectively collects clinical, molecular, pathology-and blood samples, and optional patient-reported outcomes (PROs) from nationwide participating hospitals to improve knowledge on tumor biology, responsiveness, outcomes, and quality of life.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/adenocarcinoma-of-the-small-intestine-cohort-prospectively-collecting-real-world-data-to-improve-care-and-quality-of-life-for-patients-with-a-rare-cancer/352843/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/adenocarcinoma-of-the-small-intestine-cohort-prospectively-collecting-real-world-data-to-improve-care-and-quality-of-life-for-patients-with-a-rare-cancer/352843.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why was the ACSI cohort initiated for small intestinal adenocarcinoma?","Question",{"text":112,"@type":113},"Optimal treatment strategies are unclear due to limited biological understanding and a lack of randomized controlled trials. Existing management relies on protocols from other gastrointestinal cancers, motivating a dedicated cohort to generate prospective real-world and molecular data.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What data are collected in the ACSI cohort?",{"text":117,"@type":113},"Clinical data are collected for all adult SIA patients in the Netherlands through 68 hospitals. Tumor pathology and blood samples are obtained, and optional patient-reported outcomes (PROs) are included.",{"name":119,"@type":110,"acceptedAnswer":120},"What interim enrollment and disease characteristics were reported up to June 2025?",{"text":121,"@type":113},"By June 2025, 143 patients were enrolled, and data from the first 105 patients showed a median diagnosis age of 65 years, slight male predominance, predominant duodenal tumor location, and a substantial proportion presenting with stage IV disease. Mismatch repair deficiency was detected in 28% of patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352843,1790899338,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","ORIGINAL ARTICLE  \nAdenocarcinoma of the small intestine cohort: prospectively collecting real-world data to improve care and quality of life for patients with a rare cancer  \nPascale J. M. Schafrata,b,c,d , Tim [R. de](R. de) Backa,b , Felice N. van Erninge,f , Frederieke H. van der Baang , Geraldine R. Vinke,g , Miriam Koopmang , Ruben S.A. Goedegebuureh, Louis Vermeulena,b\\# , Ignace [H.J.T. de](H.J.T. de) Hinghf, i\\#  \n, Dirkje W. Sommeijera,j\\# , and the ACSI Study Group & PLCRC Study Group on behalf of the Dutch Colorectal Cancer Group  \na Laboratory of Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC and University of Amsterdam, Amsterdam, the Netherlands; bOncode Institute, Utrecht, the Netherlands; cAmsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, the Netherlands; dDepartment of Medical Oncology, Amsterdam UMC, Amsterdam, the Netherlands; e Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands; fDepartment of Surgery, Catharina Hospital, Eindhoven, the Netherlands; gDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; hDepartment of Internal Medicine, Meander Medical Center, Amersfoort, the Netherlands; iDepartment of Epidemiology, GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands; jDepartment of Internal Medicine, Flevo Hospital, Almere, the Netherlands.  \nABSTRACT  \nBackground and purpose: Small intestinal adenocarcinoma (SIA) is a rare cancer with a poor prognosis. Optimal treatment strategies are unclear as biological understanding of the disease is limited and randomized controlled trials are lacking. Current management is based on protocols for other gastrointestinal cancers. Therefore, the AdenoCarcinoma of the Small Intestine (ACSI) cohort was initiated, a subcohort of the nationwide Prospective Dutch ColoRectal Cancer cohort (PLCRC) study. The ACSI cohort aims to provide a large-scale, prospective SIA cohort, where clinical and molecular data will be combined to improve knowledge on tumor biology, treatment responsiveness, disease outcome and patient reported outcomes (PROs). Patient/material and methods: All adult SIA patients in the Netherlands are eligible for inclusion. Nationwide inclusion is facilitated by 68 hospitals. Clinical data are collected, as well as optional PROs, pathology-and blood samples.  \nResults: Until June 2025, 143 patients have been enrolled. Data of the first 105 patients show a median age of 65 years (interquartile range 58–73) at diagnosis with a slight male predominance (60%) . Most tumors are located in the duodenum (57%) and 27% of patients present with stage IV disease, with a majority having single-site metastases (64%) . Primary tumor resection is performed in 80%, while systemic treatment is administered in 42% . Four patients did not receive any anti-tumor treatment (14%) . Mismatch repair deficiency is detected in 28% of patients.  \nInterpretation: The ACSI cohort enables structured national collection of clinical data, tumor samples and PROs of SIA patients. These data provide a valuable source for further research and improvement of care for this patient group.  \nARTICLE HISTORY  \nReceived: 28 January 2026  \nAccepted: 09 April 2026  \nPublished: 28 April 2026  \nKEYWORDS  \nsmall intestinal adenocarcinoma; prospective; real-world data; quality of life; rare cancer  \nIntroduction  \nSmall intestinal adenocarcinoma (SIA) is a rare and understudied malignancy, with a poor prognosis and a globally rising incidence [1–4] . Rare cancers account for nearly 18% of all solid malignancies; however, recent studies have indicated that survival rates for patients with rare cancers have not improved atthe same pace as those for common cancers [5–7] . This lack of progress may be due to limited scientific attention and less commercial funding opportunities for rare canc","cbCaibnCCd99dKn1","https://ap.wps.com/l/cbCaibnCCd99dKn1","pdf",276243,"English","# Abstract\n## Background and purpose\n## Patient/material and methods\n## Results\n## Interpretation\n# Introduction\n## Disease background and knowledge gaps\n## Rationale for ACSI cohort\n# Article information\n## Received, accepted, published\n## Keywords and supplemental data","[{\"question\":\"Why was the ACSI cohort initiated for small intestinal adenocarcinoma?\",\"answer\":\"Optimal treatment strategies are unclear due to limited biological understanding and a lack of randomized controlled trials. Existing management relies on protocols from other gastrointestinal cancers, motivating a dedicated cohort to generate prospective real-world and molecular data.\"},{\"question\":\"What data are collected in the ACSI cohort?\",\"answer\":\"Clinical data are collected for all adult SIA patients in the Netherlands through 68 hospitals. Tumor pathology and blood samples are obtained, and optional patient-reported outcomes (PROs) are included.\"},{\"question\":\"What interim enrollment and disease characteristics were reported up to June 2025?\",\"answer\":\"By June 2025, 143 patients were enrolled, and data from the first 105 patients showed a median diagnosis age of 65 years, slight male predominance, predominant duodenal tumor location, and a substantial proportion presenting with stage IV disease. Mismatch repair deficiency was detected in 28% of patients.\"}]","Adenocarcinoma of the small intestine cohort - prospectively collecting real-world data to improve care and quality of life for patients with a rare cancer | PDF",1790101675,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c947aa35fcdcb07cb31ef38be122b016.webp",983,1280,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d8681c366773fa2ef122e57de30396b.webp",982,1278,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72eea58c0369a6a0d36722f3e44d0287.webp",981,1277,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04965b97cdc923e0e8daa1f186f67776.webp",980,1276]